Epidemiology Study of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT ID: NCT01260324
Last Updated: 2021-02-01
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
21283 participants
OBSERVATIONAL
2008-08-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT01975324
Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT03046693
Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5%
NCT01607671
NAION Treatment With Oral Prednisolone and Erythropoietin Injection
NCT03715881
Platelet-Rich Plasma for Acute Nonarteritic Anterior Ischemic Optic Neuropathy: A Prospective Randomized Controlled Study
NCT07330713
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283).
From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NAION cases
From the study population, patients with a claim associated with an ischemic optic neuropathy diagnosis code were identified as potential NAION cases (n = 3,732). From the potential NAION cases, definite and possible NAION cases were identified using medical record review and a claims algorithm (n=1,283). Data from definite and possible NAION cases contributed to the analysis.
No intervention given in this observational study
No intervention given in this observational study
Controls
From the study population, patients without a claim associated with an ischemic optic neuropathy diagnosis code were randomly selected as controls (n = 20,000)
No intervention given in this observational study
No intervention given in this observational study
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention given in this observational study
No intervention given in this observational study
No intervention given in this observational study
No intervention given in this observational study
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older
* Had at least 183 days of continuous enrollment in the database
* No doctor visits associated with a diagnosis of ischemic optic neuropathy during the 183 days prior to cohort entry
Exclusion Criteria
* Less than 183 days of continuous enrollment in the database
* At least one doctor visit associated with a diagnosis of ischemic optic neuropathy during the 183 days prior to cohort entry
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A1481282
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.